Posted 19th June 2019 by Joshua Sewell
During my eight years at the Max Planck Institute for Molecular Genetics in Berlin, I led a protein technologies group. We developed a protein expression library, and then high-content protein arrays. In total, we made arrays with 10,000 different human proteins.
Posted 12th June 2019 by Joshua Sewell
When conducting an experiment to identify biomarkers, it is crucial to design the experiment properly. 80-90% of all biomarker populations for the last 20 years have not and cannot be reproduced, and the main reason that biomarkers fail is that these experiments are not designed properly. In this post, I will outline two ways in which experiments are poorly designed, and then outline the technological and methodological solution in a later blog.
Posted 3rd June 2019 by Joshua Sewell
There is a huge need to identify biomarkers to discern which metastatic colorectal cancer patients will benefit from treatment using Regorafenib. Despite being the latest approved drugs for the disease, Regorafenib has limited clinical efficacy and is associated with a number of side effects. However, a lot of patients are treated with Regorafenib as it is the only treatment available for patients who cannot receive anti-EGFR treatment due to K-RAS or BRAF mutation.
Posted 21st March 2018 by Jane Williams
Precision medicine in oncology requires matching each patient with treatment personalised to their genes and often the proteomic profile of their cancer. Liquid biopsies continue to gain grounds as a tool for diagnostic testing in oncology.
Posted 21st February 2018 by Jane Williams
With just 3 months to go until the Precision Medicine & Biomarkers Leaders Summit: USA, we have taken some time to reflect on the Euopean Precision Medicine & Biomarkers Leaders Summit that took place in Munich in September.
Posted 29th December 2017 by Jane Williams
Honey Reddi, Clinical Laboratory Director at the Jackson Laboratory spoke at the 4th Global Precision Medicine and Biomarkers Leader Summit. She gives us an insight on liquid biopsies in the clinic and the effectiveness of current treatment.
Posted 29th September 2017 by Jane Williams
In 1869, Thomas Ashworth first observed circulating tumour cells (CTC) in the blood of a man with metastatic cancer using an optical microscope. He postulated that “cells identical with those of cancer itself being seen in the blood may tend to throw some light upon the mode of origin of multiple tumours existing in the same person”1.
Posted 11th September 2017 by Jane Williams
Non-invasive evaluation of molecular markers has shifted from the realm of prenatal diagnosis to tracking the effect of cancer treatment and management.